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Recent evidence highlighted a role for the transcription factor, nuclear factor of activated T-cells (NFAT), in the transcription of the human
polyomavirus JCV. Here we show that NFAT is also important in the transcriptional control of the related polyomavirus, Simian Virus 40 (SV40).
Inhibition of NFAT activity reduced SV40 infection of Vero, 293A, and HeLa cells, and this block occurred at the stage of viral transcription. Both
NFAT3 and NFAT4 bound to the SV40 promoter through κB sites located within the 72 bp repeated enhancer region. In Vero cells, NFAT was
involved in late transcription, but in HeLa and 293A cells both early and late viral transcription required NFATactivity. SV40 large T-Agwas found to
increase NFAT activity and provided a positive feedback loop to transactivate the SV40 promoter.
© 2007 Elsevier Inc. All rights reserved.Keywords: Simian virus 40; JC virus; Nuclear factor of activated T-cells; NFATIntroduction
Simian virus 40 (SV40) was originally identified in the
1950s as a contaminant of early forms of the polio vaccine
(Rollison and Shah, 2001; Shah and Nathanson, 1976). It was
estimated that 30 million people may have been exposed to
SV40 contaminated vaccines between 1955 and 1963 (Rollison
and Shah, 2001; Stratton et al., 2002). Shortly after the con-
tamination was discovered, SV40 was found to be an oncogenic
DNA virus capable of causing a variety of neoplasias in
laboratory animals (Butel and Lednicky, 1999; Diamandopou-
los, 1972). Studies of those exposed to SV40 through contam-
inated vaccines found that there was insufficient evidence to
evaluate any relationship between SV40 and cancer (Stratton
et al., 2002). The current prevalence of SV40 in the human
population is unknown (Vilchez et al., 2003b), but recent
evidence has detected SV40 gene products in primary brain and
bone cancers, malignant mesotheliomas, and non-Hodgkin's
lymphoma (Pass et al., 1998; Vilchez et al., 2003a,b). Many of
these studies found evidence of SV40 infection in the cancers of⁎ Corresponding author. Fax: +1 401 863 9653.
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suggesting that SV40 may be capable of circulating within the
human population. Such evidence has led to concern that SV40
may pose a threat as an emerging human pathogen.
SV40 is a member of the polyomavirus family which en-
compasses a group of small non-enveloped double-stranded
DNAviruses. The SV40 genome can be divided into two coding
regions separated by a non-encoding regulatory region which
contains the viral promoter and the origin of DNA replication.
Like all polyomaviruses the lifecycle of SV40 is temporally
regulated. Following entry into the cell, the virus must traffic to
the nucleus where transcription of the early viral genes occurs.
Early viral gene products consist of small and large T-Antigens,
both of which are regulatory proteins that aid viral transcription,
DNA replication, and transformation. When enough early pro-
teins have been produced, the virus switches from early tran-
scription to DNA replication. Following sufficient DNA
replication, transcription of the late viral genes then occurs,
and these consist of the three viral coat proteins, VP1, VP2, and
VP3, as well as another regulatory protein called agnoprotein.
Elucidation of the regulatory components of SV40 transcrip-
tion has provided significant insight into how eukaryotic cells
regulate gene expression (Tjian, 1994). The SV40 promoter
comprises two main elements (Fig. 1a). The first contains two
Fig. 1. The SV40 promoter contains two κB sites situated in the 72 bp repeated enhancer region. (a) The SV40 promoter contains two major regions. The first is a series
of three 21 bp repeats that contain multiple Sp1 binding sites. The second region consists of two 72 bp repeated sequences that contain numerous transcription factor
binding sites, including a κB site in each 72 bp sequence. (b) Alignment of the κB sequence from SV40, JCV, HIV-LTR, and the IL-8 promoter.
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slightly. Each of these sequences contains multiple Sp1 binding
sites and this region is particularly important to early viral
transcription (Benoist and Chambon, 1981; Everett et al., 1983;
Fromm and Berg, 1982). The second element of the SV40
promoter is a region that contains two perfectly repeated 72 bp
sequences. This region was originally characterized as the
classical eukaryotic enhancer sequence and plays a role in both
early and late viral transcription depending on the cell type.
Numerous transcription factor binding sites have been identified
within the enhancer region, including sites for AP-1 and NFκB
(Macchi et al., 1989; Mermod et al., 1988).
Recent evidence from our lab has identified a role for the
transcription factor Nuclear Factor of T-cells (NFAT) in infection
by a human polyomavirus, JC virus (JCV) (Manley et al., 2006).
In the case of JCV infection, NFAT is important for both early
and late viral gene expression, and a loss of NFATactivity results
in a block to viral infection. We were able to show that NFAT
binds directly to the JCV promoter via a site that is also capable
of binding a related transcription factor, NFκB. In addition to a
role in viral transcription, NFAT activity is enhanced by early
viral gene products resulting in an amplification of viral gene
transcription. The κB site in JCV is similar to sites found in other
promoters, such as the Interleukin-8 promoter and the HIV-LTR,
that are capable of binding either NFκB or NFAT depending on
the cellular context. The κB sites of SV40 are also similar to that
of JCV (Fig. 1b). We tested to see if NFAT was also capable of
binding to the κB sites in SV40 and mediating viral tran-
scription. We found that inhibition of NFAT activity in a variety
of cell types was capable of inhibiting SV40 infection, and that
NFAT was indeed capable of binding to and acting through the
two κB sites situated in the SV40 enhancer region. We also
found that SV40 large T-Ag was capable of activating NFAT
transcription.
Results and discussion
The inhibition of NFAT activity reduces SV40 infection
To test if SV40 infection of Vero, 293A, and HeLa cells
requires NFATactivity, we pretreated cells for 6 h with a peptide
inhibitor of NFAT activation (Aramburu et al., 1999) and theninfected for 1 h with SV40. Following infection, the cells were
maintained in the inhibitor and the number of infected cells was
counted 72 h p.i. by using indirect immunofluorescence to detect
early and late viral proteins. Both T-Antigen and V-Antigen
expressions were blocked in 293A and HeLa cells (Fig. 2),
indicating a role for NFAT in viral infection of these cells. In
Vero cells, there was no effect on T-Antigen expression (Fig. 2),
but V-Antigen expression was inhibited to similar levels as those
seen with HeLa and 293A cells, suggesting that NFAT is
involved in the later stages of SV40 infection in Vero cells.
NFAT is present and active in Vero, HeLa, and 293A cells
Next we looked to see which members of the NFAT family
are expressed in Vero, HeLa, and 293A cells. There are five
members of the NFAT family (NFAT1–5), but only NFAT1–4
are responsive to calcium signaling. Western blots probing for
NFAT1–4 reveal that Vero cells express only NFAT4 (Fig. 3a),
293A cells express only NFAT3, and HeLa cells express both
NFAT3 and NFAT4.
Treatment of cells with a combination of Phorbal 12-myristate
13-acetate (PMA) and Ionomycin is the established method of
activating NFAT in a variety of cell types. To confirm that NFAT
in Vero cells, HeLa cells, and 293A cells is capable of being
activated under these conditions, we transiently transfected cells
with a reporter construct that expresses luciferase under the
control of an NFAT responsive promoter (pNFAT-luc) and treated
cells with 80 ng/ml of PMA and 2 μM Ionomycin. NFAT
transcriptional activity was generated in all three cell types under
these conditions (Fig. 3b). All subsequent experiments that
required NFAT activity were carried out under these conditions.
NFAT activates the SV40 promoter via two κB sites
As NFAT is a transcription factor, we examined the SV40
promoter for potential NFAT binding sites. JCV infection of
glial cells relies upon the direct binding of NFAT4 to a κB site
situated in the viral untranslated control region. This site had
previously been shown to be capable of binding another
transcription factor family, the NFκB family. SV40 has two
NFκB sites situated in the 72 bp repeated sequences of the
promoter (Fig. 4a). NFκB has previously been shown to bind to
Fig. 2. NFATactivity is required for SV40 infection. Vero, HeLa, and 293A cells
were treated with a cell permeable NFAT inhibitor peptide (Calbiochem) 6 h
prior to infection with SV40. Cells were infected for 1 h in the presence of the
inhibitor. Following infection, the cells were maintained in the inhibitor. Due to
the half-life of the peptide, at 24 h and 48 h p.i., cells were treated with fresh
peptide. At 72 h p.i,. cells were fixed and stained for either T-Ag (a) or V-Ag (b).
Approximately 40%, 20%, and 25% of untreated cells were infected in Vero,
HeLa, and 293A cells, respectively. All values are given as percentage of cells
infected as compared to the untreated control. Each experiment was repeated in
triplicate and used to calculate the mean and standard deviation.
Fig. 3. NFAT expression and activation in Vero, HeLa, and 293A cells. (a) Vero
and HeLa cells express NFAT4, while HeLa and 293A cells express NFAT3 as
determined by western blot analysis. Ramos cell lysates were used as a positive
control. (b) NFATactivity was measured in HeLa, Vero, and 293A cells using an
NFAT responsive luciferase reporter construct and comparing it with a luciferase
reporter construct that lacks an NFAT responsive element (TA-control). Cells
were transfected with either the NFAT reporter or the TA-control and NFATwas
activated by treating cells with 80 ng/ml of PMA and 2 μM Ionomycin. The
fold-change in luciferase activity was calculated by comparing treated to
untreated samples. The control construct did not show any increased in activity
when treated, while the NFAT reporter showed that in all three cell types NFAT
activity was triggered by treatment with PMA and Ionomycin. All values were
normalized to a TK-renilla control, and each experiment was conducted in
triplicate.
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other transcription factors have also been implicated as capable
of binding to these sites in a cell-type-dependent manner (Espel
et al., 1990; Lattion et al., 1992; Macchi et al., 1989).
To test if NFAT was activating the SV40 promoter through
these NFκB sites, we used promoter reporter assays to compare
the effect of the NFAT peptide inhibitor on both the wild-type
SV40 promoter, and an SV40 promoter in which the κB sites
have been mutated so they are no longer functional. The reporter
constructs used contained the luciferase gene under the control
of the SV40 promoter in either the early or late orientation
(pluc2/SV40E and pluc2/SV40L). To generate the reporterconstructs which lacked functional κB sites, the first two
nucleotides of each site were mutated from GG to AA (Fig. 4a).
The wild-type and mutated reporter constructs were co-
transfected into each of the cell types with a construct that
constitutively expresses the NFAT inhibitor peptide conjugated
to GFP (pGFP-VIVIT). Compared to a control construct that
only expressed GFP (phMGFP), expression of the VIVIT-GFP
peptide resulted in a decrease in both early and late wild-type
promoter activity in both HeLa and 293A cells (Figs. 4b and c).
In contrast, only late transcription was affected in Vero cells by
the expression of VIVIT-GFP (Fig. 4c). These results match
those seen when cells were treated with the NFAT peptide
inhibitor and then challenged with virus, suggesting that in HeLa
and 293A cells both early and late viral transcription utilize
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transcription.
In both HeLa and 293A cells, mutation of the κB sites
resulted in a significant decrease in promoter activity in both the
early and late orientations as compared to the wild-type
promoters (Figs. 4b and c). Consistent with NFAT only playing
a role in late transcription in Vero cells, the mutations only
affected transcription from the promoter in the late orientationFig. 4. NFATactivates both the early and late SV40 transcription via the κB sites in th
repeats (a). The NFκB/NFAT sites were mutated in the early and late promoter lucif
were mutated (G→A) are shown in red. Cells were co-transfected with either the wild-
the NFAT peptide inhibitor (pGFP-VIVIT) or a construct that only expresses GF
transfection. These experiments were carried out in the presence of 80 ng/ml of PMA a
was carried out in triplicate and the averages and standard deviations were calculate(Fig. 4c). Early transcription was unaffected by mutation of the
κB sites in Vero cells. Inhibition of NFAT by expressing VIVIT-
GFP failed to further reduce either early or late promoter
activity in any of the cells (Figs. 4b and c), suggesting that
NFAT plays only a direct role in viral transcription and not an
indirect one.
To demonstrate that NFAT binds to the SV40 promoter
during infection, we carried out chromatin immunoprecipitatione SV40 promoter. The SV40 promoter contains two κB sites situated in the 72 bp
erase reporter constructs (pluc2/SV40E and pluc2/SV40L). The nucleotides that
type or mutated promoter reporter constructs and a construct that expresses either
P as a control (phMGFP). Luciferase activity was measured 48 h following
nd 2 μM Ionomycin. All values were normalized to TK-renilla. Each experiment
d.
Fig. 5. NFAT binds directly to the SV40 promoter region. ChIP analysis was
carried out on HeLa, Vero, and 293A cells infected with SV40 for 72 h in the
absence of PMA and Ionomycin. Chromatin was immunoprecipitated with
either a monoclonal α-NFAT4 antibody (Santa Cruz Biotech. Inc.), a polyclonal
α-NFAT3 antibody (Santa Cruz Biotech. Inc.), or a mouse IgG antibody (Santa
Cruz Biotech. Inc.).
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and 293A cells was immunoprecipitated with an NFAT3
antibody, there was about a 3-fold increase in the amount of
SV40 promoter DNA as compared with DNA immunoprecipi-
tated using a non-specific IgG antibody (Fig. 5). NFAT4 was
also tested for its ability to bind to the SV40 promoter in HeLa
and Vero cells. NFAT4 appeared to bind to the SV40 promoterFig. 6. NFAT is activated by the expression of SV40 large T-Ag. Cells (in the absenc
(pNFAT-luc) and either a control construct (phMGFP) or a construct expressing SV4
(pTA-luc), which is missing the NFAT binding site in the promoter, was also testedin Vero cells but not HeLa cells (Fig. 5), suggesting that in cells
were both NFAT3 and NFAT4 are available NFAT3 will be
preferentially bound.
SV40 large T-Ag is capable of activating NFAT mediated
transcription
Previous evidence has shown that both JCV early proteins
and SV40 large T-Ag are capable of activating NFAT mediated
transcription. To see if SV40 large T-Ag was capable of
activating NFAT transcription in Vero, HeLa, and 293A cells,
we transiently transfected either a control construct (pTA-luc) or
the NFAT reporter construct (pNFAT-luc) with a construct that
expresses the SV40 large T-Ag protein under the control of the
RSV promoter (pSG5-T). Compared with a control plasmid that
expresses only GFP (phMGFP), SV40 large T-Ag was capable
of activating NFAT in all three cell types. There was a 2-fold
activation of NFAT activity in HeLa and 293A cells, while there
was a 5-fold increase in NFAT activity in Vero cells (Fig. 6).
SV40 large T-AG failed to have any effect on a reporter plasmid
that lacked the NFAT binding sites (pTA-luc).
Understanding how viruses transcribe their genes has been
fundamentally important for understanding the complexity of
eukaryotic transcriptional control mechanisms. Previously we
demonstrated that the transcription factor, nuclear factor of
activated T-cell 4 (NFAT4), binds to a κB site in the promoter of
the human polyomavirus JCV, and directly activates both early
and late viral transcription. Here we show that SV40 also utilizes
NFAT to infect a variety of cell types. In the two human cell lines
tested (293A cells and HeLa cells), NFAT3 is capable of bindinge of PMA and Ionomycin) were co-transfected with the NFAT reporter construct
0 large T-Ag (pSG5-T). The effect of SV40 T-Ag on a control reporter construct
. Luciferase activity was measured 48 h following transfection.
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activates both early and late transcription. In contrast, SV40
infection of a monkey kidney cell line (Vero cells) utilized
NFAT4 to directly activate late transcription but not early
transcription. In addition, expression of SV40 T-Ag activates
NFATmediated transcription in all three cell types, indicating a
role for NFAT in T-Ag mediated transactivation of the SV40
promoter.
NFκB has previously been shown to bind to the κB sites in
the SV40 promoter, but is also known that SV40 can infect cells
that do not express NFκB.Other factors have been shown to bind
to these κB sites but their identity is unclear. Here we identify
NFAT as another transcription factor capable of binding the κB
sites of the SV40 promoter. The ability of NFAT to bind to the κB
site in the promoter attests to the versatility of the SV40
promoter. As both NFκB and NFAT are capable of binding and
activating transcription, the number of cell types that SV40 can
infect is increased. The fact that both NFAT and NFκB can bind
to these sites in promoters such as the IL-8 promoter and HIV-
LTR depending on the signaling context, suggests that SV40 can
infect cell types that contain both NFAT and NFκB under a
variety of signaling conditions, again increasing the versatility of
the SV40 promoter.
Whether NFAT is important for both early and late tran-
scription or just early appears to be dependent on which cell is
being infected. In Vero cells, only late transcription is affected by
NFATactivity, while in HeLa and 293A cells, both early and late
are dependent on NFAT. This difference could be due to a
number of reasons. First it could merely be that the strength of
the Sp1 responsive 21 bp repeats in Vero does not require
additional activation from transcription factor sites in the
enhancer region. Second, species specific factors might play a
role, as Vero cells are green monkey kidney cells and both HeLa
and 293A cells are of human origin. Finally, the difference could
be due to the version of NFAT that is expressed in the cells. Vero
cells express NFAT4 while HeLa and 293A cells express
NFAT3.
Both JCV and SV40 are capable of activating NFAT me-
diated transcription by expression of their early viral proteins.
This appears to be a common feature of the polyomavirus
family. Both hamster and mouse polyomavirus have previously
been shown to activate NFAT via phosphorylation of
phospholipase C-gamma (PLC-γ) by the viral protein, middle
T-Ag (Brizuela et al., 1995; Kennedy et al., 1998). JCV and
SV40 do not have a middle T-Ag protein so the mechanism by
which they activate NFAT is likely to be different, but the theme
of NFAT activation to aid viral transcription appears to be
common.
The potential emergence of SV40 as a human pathogen
highlights the need to identify cellular targets for potential drug
treatment. Any target for drug treatment must be a factor that is
required for SV40 infection of a variety of cell types. As SV40
T-Ag is oncogenic, it must also result in a block to early gene
expression. Provided that SV40 requires NFAT/NFκB activity
for both early and late transcription in human cells, blocking a
combination of NFAT and NFκB activity may be one avenue of
drug treatment.Materials and methods
Cells, antibodies, and virus
Vero cells were cultured in media supplemented with 5% fetal
calf serum (Mediatech, Inc.). 293A and HeLa cells were cultured
in media supplemented with 10% fetal calf serum (Mediatech,
Inc.). Cells weremaintained in a humidified 37 °CCO2 incubator.
The SV40 strain used in these experiments and its production has
been previously described (Liu and Atwood, 2001). The
antibodies used for both western blot experiments and chromatin
immunoprecipitation analysis (NFATc2 (4G6-G5), NFATc1
(7A6), NFATc4 (H-74), NFATc3 (F-1), α-tubulin, and the normal
mouse IgG) were obtained from Santa Cruz Biotechnology.
Infection and indirect immunofluorescence
Cells were grown to ∼70% confluency infected for 1 h with
1.92×106 pfu/ml of virus in the presence of EMEM plus 2%
serum in a total volume of 250 μl. This correlates to an MOI of
approximately 10. At 3 days post-infection (p.i.), cells were fixed
in 2% paraformaldehyde for 30 min and permeabilized for 20min
in 0.2% Triton-X. Infected cells were detected either using a
monoclonal antibody (PAB597) against the major capsid protein
VP1, or a monoclonal antibody (PAB416) against SV40
T-Antigen (Oncogene). Primary antibody was detected with an
Alexaflour 488-labeled goat anti-mouse secondary antibody
(Molecular Probes). Cells were counter-stained with 0.02%
Evans blue. Positive cells were visualized on a Nikon epifluor-
escence microscope (Eclipse E800; Nikon Inc.).
Western blots
Whole cell extracts were separated on Tris–HCl Ready gels
(Bio-Rad). Proteins were transferred to nitrocellulose mem-
branes and blocked with 1× casein blocking buffer. Blots were
probed with the respective antibodies all diluted in 1× blocking
buffer, and then incubated with goat anti-mouse Alexa-Fluor
680 antibodies (Molecular Probes) diluted 1:1000 in blocking
buffer. Blots were viewed using an infrared scanner from
LICOR and analyzed using Odyssey software.
Constructs and mutagenesis
The pGFP-VIVIT construct expresses the NFAT peptide
inhibitor fused with GFP under the control of the CMV
promoter (Aramburu et al., 1999). pSG5-T is the pSG5 plasmid
(Stratagene) with the full-length SV40 large T-Antigen inserted
into the BamHI site, and constitutively expresses the SV40 T-Ag
protein (Zalvide and DeCaprio, 1995). The pGL4.13 (pluc2/
SV40E), pRL-TK, and phMGFP constructs were purchased
from Promega. The pluc2/SV40L was generated by the PCR
amplification of the SV40 promoter region of the pluc2/SV40E
construct, with primers that inserted XhoI and BglII sites at
either end. The PCR product was then directionally cloned into
the pGL4.10 construct (Promega). Therefore, both pluc2/SV40E
and pluc2/SV40L constructs carry the entire SV40 promoter
54 K. Manley et al. / Virology 372 (2008) 48–55region, are identical in sequence, and differ only in the orien-
tation of the promoter. The pRL-TK, which expresses Renilla
luciferase from the thymidine kinase promoter of HSV, and
phMGFP, which only expresses GFP from the CMV promoter,
were both purchased from Promega. The pNFAT-luc reporter
plasmid expresses firefly luciferase under the control of a
promoter that contains four repeats of the IL-2 NFAT binding
site, and the pTA-luc, which is the pNFAT-luc construct minus
any NFAT sites, was purchased from Panomics. Reporter con-
structs were mutated using the Stratgene Quikchange mutagen-
esis kit according to the manufacturers' instructions.
Transfection and luciferase assays
Transient transfections were carried out using lipofectamine
(Invitrogen) as described by the manufacturers' protocol. Vectors
were co-transfected with the Renilla luciferase control vector
(pRL-TK) (Promega). Renilla and Firefly luciferase activity were
measured 48 h post-transfection using the Promega Dual-
Luciferase Reporter Assay System. Relative luciferase units were
measured using a Berthoid Lumat LB9501 luminometer. Firefly
luciferase measurements for each experiment were normalized
using the Renilla luciferase measurements. The results of each
experiment were confirmed by three independent transfections.
Chromatin immunoprecipitation assays
Flasks (75 cm3) of cells at ∼70% confluency were infected
with 105 pfu/ml of SV40 in the presence of EMEMplus 2% serum
in a total volume of 1ml for 1 h. The cells were thenmaintained in
EMEM plus 10% serum for 2 days. The ChIP was performed
according to a protocol obtained from Santa Cruz Biotechnology.
Briefly, cells were harvested by scraping and washed twice in 1×
PBS. Cells were then treated for 8 min with 1% formaldehyde.
Cells were washed three times in ChIP Lysis buffer (Santa Cruz
Biotech. Inc.) and resuspended in 1.0 ml of ChIP lysis buffer with
high salt (Santa Cruz Biotech. Inc.). Samples were sonicated
using a Branson Sonifier 150 at power setting 2 four times for
1 min. Chromatin was pre-cleared with Protein A/G PLUSAgar-
ose (Santa Cruz Biotech. Inc.) at 4 °C for 30 min. Primary
antibody was incubated with chromatin overnight at 4 °C.
Immune complexes were harvested by Protein A/G PLUSAgar-
ose for 2 h at 4 °C. Beads were washed twice with lysis buffer and
three times with wash buffer (Santa Cruz Biotech. Inc.). Samples
were resuspended in elution buffer (Santa Cruz Biotech. Inc.) and
incubated at 67 °C overnight. DNA samples were extracted using
the Stratagene PCR purification kit according to the manufac-
turers' protocol. Sybr green quantitative PCR (Applied Biosys-
tems) was performed using 5 μl of the immunoprecipitated DNA
and primers that encompass the entire SV40 promoter region
(5′-TGGAATAGCTCAGAGGCCGAG-3′ and 5′-CATGGCCT-
GAAATAACCTCTG-3′).
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